Showing 7281-7290 of 7742 results for "".
- New Book Launched: Cosmeceuticals and Cosmetic Ingredientshttps://practicaldermatology.com/news/20141113-new_book_launched_cosmeceuticals_and_cosmetic_ingredients/2459067/"Cosmeceuticals and Cosmetic Ingredients" (McGraw Hill), the second textbook from Dr. Leslie Baumann, is now available through Amazon.com and booksellers internationally. Written for medical and skincare students and professionals, "Cosmeceuticals and Cosmetic Ingredients" focuses on the scien
- ASDS Elects New Officers and Board Membershttps://practicaldermatology.com/news/20141112-asds_elects_new_officers_and_board_members/2459071/The American Society for Dermatologic Surgery (ASDS) announced the election of Tom Rohrer,
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulc
- Foamix Pharmaceuticals Will Host Key Opinion Leader Meeting and Webcast on November 4th in New York Cityhttps://practicaldermatology.com/news/20141029-foamix_pharmaceuticals_will_host_key_opinionleader_meeting_and_webcast_on_november_4th_in_new_york_city/2459077/Foamix Pharmaceuticals Ltd. will host a Key Opinion Leader breakfast on Tuesday, November 4, 2014 from 8:00am-9:30am Eastern Time in New York City. The meeting will feature key opinion leader Mark Lebwohl, MD, who leads a renowned dermatology program in the U.S., as the Sol and Clara Kes
- Study Finds that the Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanomahttps://practicaldermatology.com/news/20141024-study_finds_that_the_use_of_melafind_reduced_benign_biopsies_by_61_in_patients_at_risk_for_melanoma/2459079/The study, conducted independently and not sponsored by MELA Sciences, Inc. had an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. 64 of those lesions were identified for biopsy and 102 were selected for continued observati
- FDA Advisory Committee Recommends Approval of Secukinumab for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20141020-fda_advisory_committee_recommends_approval_of_secukinumab_for_moderate_to_severe_plaque_psoriasis/2459081/The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates
- Novel Molecule Promising in Hyperhidrosis Pilot Studyhttps://practicaldermatology.com/news/20141016-novel_molecule_promising_in_hyperhidrosis_pilot_study/2459082/The outcome of a pilot study of BBI-4000, new compound for the topical treatment of primary axillary hyperhidrosis, support the potential for BBI-4000 to become a safe and effective treatment option for people suffering from excessive sweating. BBI-4000 is a new molecular entity from Brickell Biotec
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- Researchers to Present Gigapixel Whole-Body Camera at OSA Annual Meetinghttps://practicaldermatology.com/news/20141008-researchers_to_present_gigapixel_whole-body_camera_at_osa_annual_meeting/2459091/A new “gigapixel whole-body photographic camera” may provide an option for tracking changes in potentially cancer skin lesions. Duke University researchers who developed the imaging technology will presenting it at the The Optical Society's (OSA) 98th Annual Meeting, Frontiers in Optics, Oct. 19-23